Why the study?
Do opiates improve outcomes in patients with acute decompensated heart failure and acute pulmonary oedema?
Do opiates improve outcomes in patients with acute decompensated heart failure and acute pulmonary oedema?
Answers are grounded in this paper and cite their sources.
This editorial highlights the lack of evidence supporting the traditional use of opiates in acute pulmonary edema and warns against their potential harms, particularly respiratory suppression.
See also pp. 384–90 We read with interest Dr Sosnowski's article ‘Lack of effect of opiates in the treatment of acute cardiogenic pulmonary oedema’ in this issue of Emergency Medicine Australasia not only because it helps to dispel the persistent mythology that surrounds the use of i.v. opiates in the treatment of acute pulmonary oedema (APO), but also because it points out several of the fundamental issues that plague the current management of acute decompensated heart failure (ADHF).1 As is clear from the article, there is a dearth of good evidence to help guide the management of ADHF patients. In the current age of evidence-based medicine, this is worth noting because it places front-line providers in the difficult position of constructing their own treatment algorithms, without the tools typically available to them. Not a small matter given the prevalence and seriousness of the disease in question. Heart failure has reached near epidemic proportions with an estimated 550 000 new cases annually in the United States and a hospitalization rate that has increased 159% during the past decade.2 Although we have become more successful at treating advanced cardiac disease via aggressive medical and interventional management, we have effectively created a growing population of cardiac cripples, patients who will predictably present with exacerbation of ADHF and APO as their cardiac function progressively declines. Of equal concern, heart failure is a disease with an abysmal prognosis. With mortality rates that exceed those of myocardial infarction at both time points of 30 days and 1 year, there is a strong impetus to continue to improve the ways we provide care for this patient group.3,4 Interestingly, despite the tremendous burden heart failure places on the medical system, few prospective randomized trials have been conducted to establish best care. Most of the literature that exists, as reflected in Sosnowski's current review article, consists of small, poorly designed studies that do little to delineate the true efficacy of individual therapeutic interventions. Given the lack of good evidence to guide their practice, it is not surprising that many clinicians base their treatment decisions on their own experience, as well as the anecdotal reports provided by colleagues and instructors during their training. In this framework, it is understandable that opiates have remained an accepted part of the heart failure treatment regimen, because portions of their therapeutic effect are at least theoretically beneficial in the ADHF/APO patient.5 The most reasonable argument for using opiates in APO is that they do possess some vasodilatory properties and therefore might potentially improve cardiac output by decreasing preload and afterload.5 Regardless of whether APO presents in the setting of systolic or diastolic dysfunction, it is a state that is characterized by significant elevation of both systemic vascular resistance (i.e. afterload) and filling pressures (i.e. preload).6 These altered cardiac loading conditions, in the presence of ventricular dysfunction, prevent adequate forward flow of blood from the left ventricle and result in transmission of elevated pressures into the pulmonary vasculature with the development of pulmonary oedema. As has been increasingly reported, pulmonary oedema might develop with or without significant volume overload, suggesting that the primary issue in APO, and therefore the focus of initial therapy, should be to improve cardiac loading conditions via preload and afterload reduction.7 In this manner, the vasodilatory effect provided by opiates can be viewed as potentially beneficial. However, there are several reasons why alternate agents are more likely to be effective, and why other intrinsic properties of opiates make them ill-suited for this use. Although not well studied, the vasodilatory effect provided by morphine appears to require prohibitively large doses of the drug. In a study of 28 patients on cardiopulmonary bypass, morphine was found to provide a significant decrease in systemic vascular resistance and preload at doses of 0.5–1 mg/kg.8 Although this dose would appear to provide a beneficial haemodynamic effect in the APO patient, it would almost certainly mandate simultaneous endotracheal intubation and mechanical ventilation to effectively manage the ventilatory compromise that would predictably accompany such a large dose of i.v. narcotic. As presented in the current review article, there is little convincing clinical evidence that opiates provide reliable reduction in preload or afterload in the lower dosing range that is commonly used. Clearly, there are alternative classes of medications that provide a more consistent vasodilatory response, without the respiratory suppression that accompanies the use of i.v. opiates. Nitrates, angiotensin-converting enzyme inhibitors and nesiritide have all been shown to provide beneficial haemodynamic effects in the ADHF/APO setting, and therefore provide a safer and more efficacious means of preload and afterload reduction.9–11 The alternate, oft-cited benefit of opiates in the treatment of APO is their dose-related anxiolytic effect.12 Although it can be argued that the increase in sympathetic tone that results from the sensation of suffocation that accompanies APO is detrimental, the suggestion that anxiolysis be used as a cornerstone of initial therapy should be viewed with great scepticism. Patients with APO are anxious because they have difficulty oxygenating and ventilating, not the converse. Logically, it would follow that the most effective mechanism for decreasing the level of anxiety in an APO patient would be to focus on decreasing their work of breathing, by targeting cardiac loading conditions and decreasing pulmonary oedema, not by targeting the anxiety itself. Additionally, the anxiolysis provided by opiates is accompanied by significant respiratory suppression, an effect that is clearly undesirable in a group of patients whose respiratory status might be tenuous to begin with. Even in the unlikely event that further research identifies anxiolysis as an important part of the effective management of ADHF/APO, alternative anxiolytics are available (i.e. benzodiazepines) that provide a more reliable effect, without the concomitant respiratory suppression intrinsic to all opiates. In short, the persistent use of opiates in APO is something of a metaphor for the limitations of our current approach in ADHF. The evidence to support their use is essentially non-existent, but clear ‘practice changing’ evidence for alternate agents is not much better. As a result, a therapeutic approach that includes this potentially harmful class of medications continues to be handed down from one medical generation to the next. We are hopeful that Sosnowski's article will help close the door on the use of opiates in acute heart failure syndromes, and also prompt more investigators to gather the evidence needed to clearly define what is best care of the ADHF/APO patient.
No takes yet. Share an insight, caveat, or question.
Hermann et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: